Trials / Recruiting
RecruitingNCT06774339
Biomarkers and Inflammation in Solid Organ Transplantation: Relationship With Short- and Long-Term Outcomes
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, tissue-based, low-risk, non-pharmacological study that will include adult patients undergoing solid organ transplantation (heart, liver, lung, kidney) followed at the following Units of the IRCCS Azienda Ospedaliero-Universitaria di Bologna (IRCCS AOUBO): * Heart Failure and Transplants (heart-lung) * Internal Medicine for the Treatment of Severe Organ Failures (liver) * Nephrology, Dialysis, and Transplantation (kidney).
Detailed description
The aim of this study is to perform objective biological measurements of inflammation and cellular senescence (i.e., plasma profiles of cytokines, inflammatory miRNAs, circulating free DNA, extracellular vesicles), immunosenescence (i.e., circulating and tissue-based leukocyte profiles of aging), and systemic and tissue aging (i.e., epigenetic clocks) in the collected cohort. These measures may help to stratify patients at higher risk of transplant failure (graft damage) or those at higher risk of cardiovascular, renal, metabolic, neoplastic complications, or increased mortality. Additionally, the study aims to implement therapeutic or prophylactic measures based on biological stratification to prevent the progression of biological damage. It is also important to highlight that the identification of markers of cellular senescence, immunosenescence, and epigenetic aging in the recipient could define patterns that guide more appropriate and personalized immunosuppressive treatments.
Conditions
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2031-12-01
- Completion
- 2031-12-01
- First posted
- 2025-01-14
- Last updated
- 2025-01-14
Locations
3 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06774339. Inclusion in this directory is not an endorsement.